The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has issued new recommendations on immunizations, including influenza, serogroup B meningococcal, and human papillomavirus (HPV) vaccination.
While the ACIP is continuing to recommend that all persons aged ≥6 months receive an annual vaccination against influenza, the Committee did not renew the previous year’s preference for using the intranasal spray influenza vaccine (eg, LAIV) instead of the influenza vaccine injection (eg, IIV) in healthy children aged 2–8 when immediately available. The previous recommendation was based on data that suggested that the intranasal spray vaccine may offer superior protection for children in this age group. The decision to not renew this recommendation was based on new data from more recent influenza seasons which have not confirmed these previous findings. The ACIP now recommends an annual influenza vaccine for children aged ≥6 months with no preference states for either formulation.
The ACIP also voted to recommend serogroup B meningococcal vaccination for individuals ≥10 years of age at increased risk for meningococcal disease, including those with persistent complement component deficiencies, with anatomic or functional asplenia, microbiologists routinely exposed to isolates of Neisseria meningitides, and individuals identified to be at increased risk because of a serogroup B meningococcal disease outbreak. In October 2014, Pfizer’s Trumenba (Meningococcal Group B Vaccine) was granted accelerated approval by the Food and Drug Administration (FDA) for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10–25 years of age.